Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused treatment for Molybdenum Cofactor Deficiency (MoCD). Origin is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment for MoCD to market as quickly as possible.